Stahl Neil's most recent trade in Regeneron Pharmaceuticals, Inc. was a trade of 304 Common Stock done at an average price of $730.8 . Disclosure was reported to the exchange on Dec. 16, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 16 Dec 2024 | 304 | 48,829 (0%) | 0% | 730.8 | 222,166 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 09 Dec 2024 | 466 | 49,133 (0%) | 0% | 787 | 366,742 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 13 Aug 2024 | 500 | 49,599 (0%) | 0% | 0 | Common Stock | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 08 Aug 2024 | 1,883 | 53,007 (0%) | 0% | 1084.6 | 2,042,321 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 08 Aug 2024 | 1,708 | 51,299 (0%) | 0% | 1085.0 | 1,853,197 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 08 Aug 2024 | 1,006 | 54,890 (0%) | 0% | 1083.8 | 1,090,263 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 08 Aug 2024 | 900 | 50,099 (0%) | 0% | 0 | Common Stock | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 08 Aug 2024 | 300 | 50,999 (0%) | 0% | 1086.2 | 325,845 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 08 Aug 2024 | 200 | 55,896 (0%) | 0% | 1082.7 | 216,538 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 08 Aug 2024 | 100 | 56,096 (0%) | 0% | 1081.8 | 108,183 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 02 Aug 2024 | 23,638 | 74,637 (0%) | 0% | 555.7 | 13,134,927 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 02 Aug 2024 | 23,638 | 45,000 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 02 Aug 2024 | 18,441 | 56,196 (0%) | 0% | 1093.5 | 20,165,049 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 26 Feb 2024 | 1,020 | 50,999 (0%) | 0% | 0 | Common Stock | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 07 Feb 2024 | 3,127 | 54,334 (0%) | 0% | 950.4 | 2,971,995 | Common Stock | |
| Regeneron Pharma | Stahl Neil | EVP Research and Development | 07 Feb 2024 | 1,894 | 58,062 (0%) | 0% | 948.7 | 1,796,819 | Common Stock | |
| Regeneron Pharma | Stahl Neil | EVP Research and Development | 07 Feb 2024 | 1,237 | 53,097 (0%) | 0% | 951.5 | 1,176,993 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 07 Feb 2024 | 1,059 | 52,038 (0%) | 0% | 952.5 | 1,008,687 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 07 Feb 2024 | 601 | 57,461 (0%) | 0% | 949.4 | 570,619 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 07 Feb 2024 | 100 | 59,956 (0%) | 0% | 947.3 | 94,734 | Common Stock | |
| Regeneron Pharma | Stahl Neil | EVP Research and Development | 07 Feb 2024 | 19 | 52,019 (0%) | 0% | 953 | 18,107 | Common Stock | |
| Regeneron Pharma | Stahl Neil | EVP Research and Development | 02 Feb 2024 | 30,750 | 0 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Regeneron Pharma | Stahl Neil | EVP Research and Development | 02 Feb 2024 | 30,750 | 82,769 (0%) | 0% | 399.7 | 12,289,545 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 02 Feb 2024 | 22,713 | 60,056 (0%) | 0% | 956.6 | 21,728,391 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 08 Dec 2023 | 3,059 | 3,059 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 08 Dec 2023 | 853 | 52,744 (0%) | 0% | 0 | Common Stock | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 08 Dec 2023 | 809 | 51,891 (0%) | 0% | 843.8 | 682,626 | Common Stock | |
| Regeneron Pharma | Stahl Neil | EVP Research and Development | 08 Dec 2023 | 725 | 52,019 (0%) | 0% | 844.1 | 611,965 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 21 Aug 2023 | 50,000 | 30,750 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 21 Aug 2023 | 50,000 | 103,100 (0%) | 0% | 399.7 | 19,983,000 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 21 Aug 2023 | 38,335 | 64,765 (0%) | 0% | 833.4 | 31,948,006 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 21 Aug 2023 | 6,309 | 58,456 (0%) | 0% | 840.5 | 5,302,904 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 21 Aug 2023 | 4,574 | 53,882 (0%) | 0% | 841.4 | 3,848,609 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 21 Aug 2023 | 782 | 53,100 (0%) | 0% | 842.2 | 658,569 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 16 Dec 2022 | 4,063 | 4,063 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 16 Dec 2022 | 1,101 | 53,100 (0%) | 0% | 0 | Common Stock | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 09 Dec 2022 | 466 | 51,999 (0%) | 0% | 753.3 | 351,028 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 09 Dec 2022 | 330 | 52,465 (0%) | 0% | 0 | Common Stock | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 95,000 | 147,795 (0%) | 0% | 270.4 | 25,690,850 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 95,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 71,218 | 76,577 (0%) | 0% | 613 | 43,656,634 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 4,112 | 56,664 (0%) | 0% | 614.3 | 2,526,207 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 3,931 | 68,092 (0%) | 0% | 610.5 | 2,399,836 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 3,218 | 60,776 (0%) | 0% | 613.5 | 1,974,211 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 3,044 | 72,023 (0%) | 0% | 609.6 | 1,855,683 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 2,076 | 63,994 (0%) | 0% | 612.4 | 1,271,405 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 2,022 | 66,070 (0%) | 0% | 611.4 | 1,236,332 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 1,610 | 55,054 (0%) | 0% | 615.5 | 990,939 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 724 | 75,677 (0%) | 0% | 607.5 | 439,808 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 610 | 75,067 (0%) | 0% | 608.7 | 371,307 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 535 | 54,519 (0%) | 0% | 616.4 | 329,774 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 521 | 53,574 (0%) | 0% | 618.3 | 322,119 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 502 | 53,072 (0%) | 0% | 619.6 | 311,059 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 424 | 54,095 (0%) | 0% | 617.4 | 261,790 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 335 | 52,795 (0%) | 0% | 0 | Common Stock | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 177 | 52,895 (0%) | 0% | 620.1 | 109,759 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 176 | 76,401 (0%) | 0% | 606.8 | 106,793 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 04 Aug 2022 | 100 | 52,795 (0%) | 0% | 621.1 | 62,111 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 11 Dec 2021 | 753 | 53,130 (0%) | 0% | 664.3 | 500,248 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 08 Dec 2021 | 12,494 | 12,494 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 08 Dec 2021 | 2,926 | 53,883 (0%) | 0% | 0 | Common Stock | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 03 Dec 2021 | 72,500 | 101,309 (0%) | 0% | 179.1 | 12,986,925 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 03 Dec 2021 | 72,500 | 0 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 03 Dec 2021 | 50,352 | 50,957 (0%) | 0% | 632.4 | 31,845,122 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 03 Dec 2021 | 4,605 | 4,605 (0%) | 0% | 0 | Common Stock | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 03 Dec 2021 | 4,605 | 28,809 (0%) | 0% | 0 | Common Stock | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 14 May 2021 | 40,000 | 72,500 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 14 May 2021 | 40,000 | 64,280 (0%) | 0% | 179.1 | 7,165,200 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 14 May 2021 | 27,775 | 36,505 (0%) | 0% | 516.7 | 14,351,065 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 14 May 2021 | 12,500 | 0 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 14 May 2021 | 12,500 | 49,005 (0%) | 0% | 52.0 | 650,375 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 14 May 2021 | 10,336 | 28,086 (0%) | 0% | 519.5 | 5,369,242 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 14 May 2021 | 7,204 | 41,801 (0%) | 0% | 516.7 | 3,722,235 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 14 May 2021 | 3,806 | 24,280 (0%) | 0% | 520.2 | 1,979,767 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 14 May 2021 | 3,379 | 38,422 (0%) | 0% | 518.6 | 1,752,451 | Common Stock | |
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 14 May 2021 | 435 | 24,280 (0%) | 0% | 0 | Common Stock | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 09 Dec 2020 | 17,500 | 17,500 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 09 Dec 2020 | 1,688 | 24,715 (0%) | 0% | 0 | Common Stock | ||
| Regeneron Pharma | Neil Stahl | EVP Research and Development | 09 Dec 2020 | 750 | 20,979 (0%) | 0% | 0 | Common Stock |